US5308607A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions of alkylbenzenes for visualization of the gastrointestinal tract using X-ray contrast
Assignee: GE Healthcare AS
•
Filing: 1993-02-04
•
Granted: 1994-05-03
•
Expires: 2013-02-04
Abstract
Abstract Disclosed are contrast agents of the formula <IMAGE> contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract wherein R=C1-C25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy, lower-alkoxy carbonyl or lower-alkoxy-carbonyloxy, (CR1R2)p-(CR3=CR4)mQ, or (CR1R2)p-C 3BOND C-Q; R1, R2, R3 and R4 are independently H, lower-alkyl, optionally substituted with halo; n is 1-5; m is 1-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl.
Inventors
- 👤 Kurt A. Josef
- 👤 Edward R. Bacon
- 👤 Kimberly G. Estep
- 👤 Carl R. Illig
- 👤 Brent D. Douty
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:22
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; C; C07; C07C; C07C17/00; C07C17/35; C07C17/354; A61K49/0404; A61K49/0409; A61K49/0433; A61K49/0438; A61K49/0447; A61K49/0461; C07C17/093; C07C17/10; C07C17/12; C07C17/26; C07C17/263; C07C17/2635; C07C25/00; C07C25/02; C07C25/24; C07C69/00; C07C69/62; C07C69/65
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
181 words
An orally or rectally administerable x-ray contrast composition for visualization of the gastrointestinal tract comprising a contrast agent having the formula, or a pharmaceutically acceptable salt thereof: ##STR15## wherein R is methyl, ethyl, n-propyl, C 4 -C 25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy or lower-alkoxy carbonyl (CR 1 R 2 ) p --(CR 3 ═CR 4 ) m Q, or (CR 1 R 2 ) p --C.tbd.C--Q; R 1 , R 2 , R 3 and R 4 are independently H, lower-alkyl optionally]substituted with halo; n is 2-5; m is 2-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl in an aqueous, pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier containing at least one surfactant selected from the group consisting of a zwitterionic surfactant, trimethylammonium bromide, sodium lauryl sulfate, sodium heptadecyl sulphate, alkyl benzenesulphonic acid, sodium butylnaphthalene sulfonate, sulphosuccinate, carboxylic esters, carboxylic amides, ethoxylated alkylphenols and ethoxylated aliphatic alcohols, sorbitan esters, polyoxyethylene alkyl ethers and polyoxyethylene sorbitan fatty acid esters.
Claim 2
Dependent Claim
181 words
An orally or rectally administerable x-ray contrast composition for visualization of the gastrointestinal tract comprising a contrast agent having the formula, or a pharmaceutically acceptable salt thereof: ##STR15## wherein R is methyl, ethyl, n-propyl, C 4 -C 25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy or lower-alkoxy carbonyl (CR 1 R 2 ) p --(CR 3 ═CR 4 ) m Q, or (CR 1 R 2 ) p --C.tbd.C--Q; R 1 , R 2 , R 3 and R 4 are independently H, lower-alkyl optionally]substituted with halo; n is 2-5; m is 2-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl in an aqueous, pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier containing at least one surfactant selected from the group consisting of a zwitterionic surfactant, trimethylammonium bromide, sodium lauryl sulfate, sodium heptadecyl sulphate, alkyl benzenesulphonic acid, sodium butylnaphthalene sulfonate, sulphosuccinate, carboxylic esters, carboxylic amides, ethoxylated alkylphenols and ethoxylated aliphatic alcohols, sorbitan esters, polyoxyethylene alkyl ethers and polyoxyethylene sorbitan fatty acid esters.
Claim 3
Dependent Claim
24 words
The x-ray contrast composition of claim 1 wherein said contrast agent is selected from the group consisting of: 1,3,5-triethyl-2,4,6-triiodobenzene, 1,3,5-tri-(3-methylbutyl)-2,4,6-triiodobenzene, 1,3,5-tri-N-pentyl-2,4,6-triiodobenzene, 1,3,5-tri-N-butyl-2,4,6-triiodobenzene and 1,3,5-tri-(4-methylpentyl)-2,4,6-triiodobenzene.
Claim 4
Dependent Claim
33 words
The x-ray contrast composition of claim 1 wherein said contrast agent is selected from the group consisting of: 1,3,5-tri-N-propyl-2,4,6-triiodobenzene, 1,3,5-tri-N-heptyl-2,4,6-triiodobenzene, 1,3,5-tri-N-hexyl -2,4,6-triiodobenzene, 2-(4-iodophenyl)nonane, 9-(p-iodophenyl)-10-undecenoic acid, and ethyl ester and (E)-11-(p-iodophenyl)-9-undecenoic acid, ethyl ester.
Claim 5
Dependent Claim
25 words
The x-ray contrast composition of claim 1 wherein said surfactant is present of from about 0.01% w/v to about 15% w/v in said aqueous composition.
Claim 6
Independent Claim
208 words
A method of carrying out x-ray examination of the gastrointestinal tract of a patient in need of such examination which comprises orally or rectally administering to the patient an x-ray contrast composition comprising an x-ray contrast agent, or a pharmaceutically acceptable salt thereof, having the formula; ##STR16## wherein R is methyl, ethyl, n-propyl, C 4 -C 25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy or lower-alkoxy carbonyl (CR 1 R 2 ) p --(CR 3 ═CR 4 ) m Q, or (CR 1 R 2 ) p --C.tbd.C--Q; R 1 , R 2 , R 3 and R 4 are independently H, lower-alkyl optionally]substituted with halo; n is 2-5; m is 2-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl in an aqueous, pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier containing at least one surfactant selected from the group consisting of a zwitterionic surfactant, trimethylammonium bromide, sodium lauryl sulfate, sodium heptadecyl sulphate, alkyl benzenesulphonic acid, sodium butylnaphthalene sulfonate, sulphosuccinate, carboxylic esters, carboxylic amides, ethoxylated alkylphenols and ethoxylated aliphatic alcohols, sorbitan esters, polyoxyethylene alkyl ethers and polyoxyethylene sorbitan fatty acid esters; and performing an x-ray examination of the patient.
Claim 7
Independent Claim
208 words
A method of carrying out x-ray examination of the gastrointestinal tract of a patient in need of such examination which comprises orally or rectally administering to the patient an x-ray contrast composition comprising an x-ray contrast agent, or a pharmaceutically acceptable salt thereof, having the formula; ##STR16## wherein R is methyl, ethyl, n-propyl, C 4 -C 25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy or lower-alkoxy carbonyl (CR 1 R 2 ) p --(CR 3 ═CR 4 ) m Q, or (CR 1 R 2 ) p --C.tbd.C--Q; R 1 , R 2 , R 3 and R 4 are independently H, lower-alkyl optionally]substituted with halo; n is 2-5; m is 2-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl in an aqueous, pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier containing at least one surfactant selected from the group consisting of a zwitterionic surfactant, trimethylammonium bromide, sodium lauryl sulfate, sodium heptadecyl sulphate, alkyl benzenesulphonic acid, sodium butylnaphthalene sulfonate, sulphosuccinate, carboxylic esters, carboxylic amides, ethoxylated alkylphenols and ethoxylated aliphatic alcohols, sorbitan esters, polyoxyethylene alkyl ethers and polyoxyethylene sorbitan fatty acid esters; and performing an x-ray examination of the patient.
Claim 8
Dependent Claim
24 words
The method of claim 5 wherein said contrast agent is selected from the group consisting of: 1,3,5-triethyl-2,4,6-triiodobenzene, 1,3,5-tri-(3-methylbutyl) -2,4,6-triiodobenzene, 1,3,5-tri-N-pentyl,2,4,6-triiodobenzene, 1,3,5-tri-N-butyl-2,4,6-triiodobenzene and 1,3,5-tri-(4-methylpentyl) -2,4,6-triiodobenzene.
Claim 9
Dependent Claim
31 words
The method of claim 5 wherein said contrast agent is selected from the group consisting of: 1,3,5-tri-N-propyl-2,4,6-triiodobenzene, 1,3,5-tri-N-heptyl -2,4,6-triiodobenzene, 1,3,5-tri-N-hexyl-2,4,6-triiodobenzene, 2-(4-iodophenyl)nonane, 9-(p-iodophenyl)-10-undecenoic acid, and ethyl ester and (E)-11-(p-iodophenyl)-9-undecenoic acid, ethyl ester.
Claim 10
Dependent Claim
32 words
The method of claim 5 wherein said contrast agent administered to said patient contains from about 0.1 to about 16 g iodine/kg body weight for regular x-ray visualization of the gastrointestinal tract.
Claim 11
Dependent Claim
32 words
The method of claim 5 wherein said contrast agent administered to said patient contains from about 1 to about 600 mg iodine/kg body weight for CT scan visualization of the gastrointestinal tract.
References Cited (Backward Citations)
US1867766A
Cited
US2183552A
Cited
US2186960A
Cited
US2348231A
Cited
US2622100A
Cited
US3196080A
Cited
FR1481943A
Cited
US3361700A
Cited
US3647864A
Cited
US3825591A
Cited
US4175544A
Cited
US4359454A
Cited
US4567280A
Cited
CA1259565A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-05-02 | 1997-11-01 | 1998-05-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-05-02 | 2001-11-01 | 2002-05-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-05-02 | 2005-11-01 | 2006-05-03 | $7700.00 | Window Closed / Lapsed |